Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Efficient Delivery of Optimized Painless Nerve Growth Factors to the Central Nervous System to Treat Spinal Cord Injuries

Award Number: R01NS140655
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/09/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2030

Group Awards By:

View Award Description

Efficient Delivery of Optimized Painless Nerve Growth Factors to the Central Nervous System to Treat Spinal Cord Injuries - Project Summary The incidence rate for traumatic spinal cord injuries (SCIs) in the United States is estimated to be 54 cases per million people or 17,900 new cases each year. SCIs have devastating consequences for the physical, emotional, social, and vocational well-being of patients. The direct cost for the care of SCI patients is staggering at $1.1-5.2 million per patient over their lifespan. Compared to civilian SCIs, SCIs in battlefield shows increased severity and poorer neurological recovery. Delayed access to surgical spinal decompression and stabilization after a SCI is the main cause for poor outcome. Therefore, treatments that can be used through systematic injection, when surgical intervention is delayed, in order to limit the secondary injury and promote regeneration is of urgent need. Advances in medical care of SCIs have taken place in the past two decades, however, effective treatments are still limited. Pharmacological strategies, directly working on endogenous neurons, is highly effective due to their neuroprotective and neuroregenerative capabilities. Nerve growth factor (NGF) is the first discovered neurotrophin that plays a major role in the neural development of the central nervous system (CNS). However, NGF is not currently available to patients due to its 1) poor penetration into the CNS, 2) limited duration of bioavailability, and 3) enhanced nociceptor response. To address these issues and provide an effective solution for SCI treatment, we propose to utilize a double- encapsulation system to achieve effective delivery and controlled-release of painless NGF variant (NGFp), which can preserve, protect, and regenerate the injured neurons to improve neurologic outcomes in spinal cord injuries while dissipating pain. Specifically, we are applying a novel nanotechnology platform named “nanocapsules” to effectively deliver NGFp into the spinal cord facilitated by choline transporters. Moreover, the double- encapsulation system can entrap NGF nanocapsules within double emulsions to precisely control the release kinetics of nanocapsules. Lastly, we will deliver NGFp, which has a reduced nociceptive response, but potent neurotrophic and neuroprotective capability compared to wild-type NGF. Success of this project will provide an effective treatment for SCI patients to improve neurologic outcomes and quality of life.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $610,447 )
2026	2026	THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND	6823 SAINT CHARLES AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	7/23/2026	NON-COMPETING CONTINUATION	$610,447
														Subtotal = $610,447

Issue Date FY: 2025 ( Subtotal = $624,329 )
2025	2025	THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND	6823 SAINT CHARLES AVE	NEW ORLEANS	LA	70118	ORLEANS	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/9/2025	NEW	$624,329
														Subtotal = $624,329

Grand Total All Awards = $1,234,776

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Efficient Delivery of Optimized Painless Nerve Growth Factors to the Central Nervous System to Treat Spinal Cord Injuries

Award Number: R01NS140655

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/09/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer